Cookies

Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subspecialties Retina

Monkey See?

Bardet-Biedl syndrome (BBS) – a rare form of retinitis pigmentosa (RP) that begins with degeneration of the macula – affects central vision and is therefore particularly debilitating, even in its early stages. To date – and despite ongoing research, there is no proven effective treatment for any form of RP, and so, beyond providing a diagnosis, clinicians can do very little for patients.

Now, a team of researchers at Oregon Health and Sciences University, USA, have identified a gene mutation associated with BBS in a family of rhesus macaques, which could kick off development of cell and gene therapies for treating the condition in humans.

Inspired by the success of Luxturna – the first gene therapy for retinal disease to achieve FDA approval – the team focused their attention on the lack of appropriate animal models for retinal diseases. They surveyed the retinal phenotypes of over 1200 rhesus macaques, eventually identifying a family with a frameshift mutation in the BBS7 gene.

Although most cases of BBS are associated with mutations in the BBS1 and BBS10 genes, the team believe the rare BBS7 mutation can serve as a broader model for translational research. “Photoreceptor replacement therapy is an active area of research, and the information gained from our monkey BBS7 model is likely to generalize not only to all forms of BBS, but to all forms of RP and other photoreceptor degenerations,” says Martha Neuringer, Professor of Neuroscience at the Oregon National Primate Research Center and Research Associate Professor of Ophthalmology in the OHSU School of Medicine.

With funding from Research to Prevent Blindness and the National Eye Institute, the team are now working to propagate the BBS7 model; “In the future, we hope to be able to establish a colony of animals as a valuable resource for testing a variety of therapeutic strategies, including gene- and cell-based therapies,” adds Neuringer. “Our aim is to demonstrate the efficacy of such therapies, enabling them to be used in the clinic to preserve the sight of retinal degeneration patients.”

Enjoy our FREE content!

Log in or register to gain full unlimited access to all content on the The Ophthalmologist site. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Lauren Robertson

Deputy Editor at The Ophthalmologist.

Newsletter

Send me the latest from The Ophthalmologist.

Sign up now

Most Popular

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register